Thanks CJ it literally gives me chills to watch that video with Dr Massague and think MSK chose Peregrine to work with! Literally unbelievable were Peregrine is today phase III fully enrolled anyday, look ins any week, we as long investors have an unbelievable opportunity to invest at prices were pphm is at today. To think the head of MSK chose to work with Peregrine and now six months later after seeing Bavituximab first hand in the lab again Dr Massague chooses Peregrines Bavituximab to be featured at a conference were he the head of MSK is chairing.
Wow is all I can say!
As James keeps saying no way is Gilead or Astra Zenica or Bristol going to wait for more data for a pissing match.